Dangers of low-dose corticosteroid therapy in rheumatoid arthritis

Bulletin on the Rheumatic Diseases

Volumn 46, Issue 4, 1997, Pages

  Ramos Remus, Cesar ^a   Russell, Anthony S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; PREDNISONE;

HUMAN; REVIEW; RHEUMATOID ARTHRITIS; TIME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PREDNISONE; TIME FACTORS;

EID: 18544394978     PISSN: 00075248     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Laan RFJM, Van Riel PLCM, Van Erning LJThO, Lemmens JAM, Rujis SHJ, Van de Putte LBA: Vertebral osteoporosis in rheumatoid arthritis patients: effect of low-dose prednisone therapy Br J Rheumatol 31:573-574, 1992 [letter].
2. Laan RFJM, van Riel PLCM, van de Putte LBA, van Erning LJThO, van't Hof MA, Lemmens JAM: Low-dose prednisone induced rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 119:63-68, 1993.
3. Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352-364, 1990.
4. Saag K, Koehnke R, Caldwell JR, et al: Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115-123, 1994.
5. Kirwan JR and Rheumatism Council Low-Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333:142-146, 1995.
6. Gulko PS, Mullow AL: Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol 14:199-206, 1996.
7. Caldwell JR, Furst DE: The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 21:1-11, 1991.
8. Sherrer YS, Bloch DA, Mitchell DM, Roth SH, Wolfe F, Fries JF: Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumatol 14:705-709, 1987.
9. Fries JF, Williams CA, Bloch DA, Michell BA: Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 91:213-222, 1991.
10. Wolfe F, Mitchell DM, Sibley JT, et al: The mortality of rheumatoid arthritis. Arthritis Rheum 37:481-494, 1994.
11. McDougall R, Sibley J, Haga M, Russell AS: Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21:1207-1213, 1994.
12. Fries JF, Williams CA, Ramsey DR, Bloch DA: The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36:297-306, 1993.
13. Ramos-Remus C, Sibley J, Russell AS: Steroids in rheumatoid arthritis: the honeymoon revisited. J Rheumatol 19:667-670, 1992.
14. Porter D: Glucocorticoids and joint destruction in rheumatoid arthritis. N Engl J Med 333:1569, 1995 [letter].
15. Van Gestel AM, Laan RFJ, Haagsma CJ, Van de Putte LBA, Van Riel PLCM: Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol 34:347-351, 1995.
16. Goldsmith CH: Proceedings of the Fourth Joint WHO/ILAR task force meeting on rheumatic diseases; July 10, 1991; Geneva. WHO Document no. DBO-TFRD-91.1
17. Criswell LA, Redfearn WJ: Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis. Arthritis Rheum 37:476-480, 1994.
18. Criswell LA, Henke CJ: What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? J Rheumatol 22:829-835, 1995.
19. Markham A, Bryson HM: Deflazacort: a review of its pharmacological properties and therapeutic efficacy. Drugs 50:317-333, 1995.